AstraZeneca partners with insitro on AI — driven drug discovery for MASH, cardiomyopathies
AstraZeneca entered a drug discovery collaboration and licensing agreement with insitro to develop AI-driven treatments for MASH and cardiomyopathies. Insitro will receive $40 million upfront, with eligibility for up to approximately $1.46 billion in development and commercial milestones. Potential single-digit royalti